Lindsay A. Renfro
Lindsay A. Renfro received a Bachelor of Science in mathematics, summa cum laude, with a minor in computer science from Texas Woman’s University in 2005. She continued her studies at Rice University before moving to Baylor University where she received a Master of Science in statistics in 2007 and a Ph.D. in statistics in 2011.
Early in her education, a TWU instructor advised Renfro to choose math as a major, something she had not considered. Faculty at Texas Woman’s encouraged her also to attend graduate school after completing the undergraduate degree. She completed a summer internship at the Mayo Clinic in 2009 and returned there after graduation to begin her professional career as a faculty biostatistician in 2011. With many accomplishments, she moved quickly into positions of leadership and increased responsibility. Renfro currently serves as senior associate consultant and associate professor of biostatistics at the Mayo Clinic in Rochester, Minnesota. Her research interests center on improving the efficiency and ethics of clinical trials and patient care in oncology. Renfro was instrumental in developing an internationally accessible diagnostic tool used by medical professionals in the treatment and recommendations for colon cancer patients. Research highlights include statistical research, cancer clinical trials and teaching statistics to non-statisticians, from M.D.s to other Ph.Ds. Her goals in areas significant to patient care include age effect in advanced colorectal cancer, the BMI effect in advanced colorectal cancer and the development of a clinical calculator for Stage III colon cancer. Renfro is the author or co-author of more than 42 articles on her research subject published in the Journal of Clinical Oncology, Journal of Geriatric Oncology, Journal of the National Cancer Institute and the New England Journal of Medicine. She continues to advance statistical research to identify new ways of conducting cancer clinical trials, using molecular data and personalized medicine to make trials more efficient.